State Street’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $160M | Buy |
8,916,090
+2,302,776
| +35% | +$43.6M | ﹤0.01% | 1185 |
|
|
2026
Q1 | $144M | Buy |
6,613,314
+13,873
| +0.2% | +$269K | 0.01% | 1155 |
|
|
2025
Q4 | $142M | Buy |
6,599,441
+1,294,534
| +24% | +$27.3M | ﹤0.01% | 1154 |
|
|
2025
Q3 | $102M | Buy |
5,304,907
+609,880
| +13% | +$10.9M | ﹤0.01% | 1327 |
|
|
2025
Q2 | $80.3M | Buy |
4,695,027
+626,555
| +15% | +$26.7M | ﹤0.01% | 1423 |
|
|
2025
Q1 | $260M | Sell |
4,068,472
-1,392
| -0% | -$147K | 0.01% | 750 |
|
|
2024
Q4 | $495M | Sell |
4,069,864
-200,902
| -5% | -$24.6M | 0.02% | 543 |
|
|
2024
Q3 | $533M | Buy |
4,270,766
+128,973
| +3% | +$17.8M | 0.02% | 527 |
|
|
2024
Q2 | $654M | Buy |
4,141,793
+2,019,302
| +95% | +$259M | 0.03% | 458 |
|
|
2024
Q1 | $275M | Sell |
2,122,491
-276,587
| -12% | -$33.9M | 0.01% | 714 |
|
|
2023
Q4 | $231M | Buy |
2,399,078
+413,502
| +21% | +$39.7M | 0.01% | 765 |
|
|
2023
Q3 | $241M | Buy |
1,985,576
+71,844
| +4% | +$8.12M | 0.01% | 688 |
|
|
2023
Q2 | $219M | Buy |
1,913,732
+139,756
| +8% | +$18M | 0.01% | 755 |
|
|
2023
Q1 | $245M | Sell |
1,773,976
-167,768
| -9% | -$21.8M | 0.01% | 694 |
|
|
2022
Q4 | $252M | Buy |
1,941,744
+6,761
| +0.3% | +$783K | 0.01% | 670 |
|
|
2022
Q3 | $214M | Sell |
1,934,983
-381,500
| -16% | -$38.5M | 0.01% | 713 |
|
|
2022
Q2 | $174M | Buy |
2,316,483
+258,808
| +13% | +$19M | 0.01% | 811 |
|
|
2022
Q1 | $161M | Buy |
2,057,675
+194,320
| +10% | +$14.9M | 0.01% | 977 |
|
|
2021
Q4 | $168M | Buy |
1,863,355
+71,261
| +4% | +$6.09M | 0.01% | 957 |
|
|
2021
Q3 | $166M | Buy |
1,792,094
+105,749
| +6% | +$8.15M | 0.01% | 939 |
|
|
2021
Q2 | $131M | Sell |
1,686,345
-344,960
| -17% | -$26.2M | 0.01% | 1092 |
|
|
2021
Q1 | $151M | Buy |
2,031,305
+172,233
| +9% | +$15.9M | 0.01% | 934 |
|
|
2020
Q4 | $317M | Sell |
1,859,072
-40,180
| -2% | -$5.95M | 0.02% | 612 |
|
|
2020
Q3 | $267M | Buy |
1,899,252
+63,307
| +3% | +$9.62M | 0.02% | 604 |
|
|
2020
Q2 | $294M | Sell |
1,835,945
-218,849
| -11% | -$29.8M | 0.02% | 563 |
|
|
2020
Q1 | $201M | Buy |
2,054,794
+36,383
| +2% | +$4.16M | 0.02% | 606 |
|
|
2019
Q4 | $260M | Sell |
2,018,411
-174,644
| -8% | -$17.6M | 0.02% | 632 |
|
|
2019
Q3 | $165M | Buy |
2,193,055
+832,067
| +61% | +$98.3M | 0.01% | 750 |
|
|
2019
Q2 | $207M | Buy |
1,360,988
+7,522
| +0.6% | +$914K | 0.02% | 686 |
|
|
2019
Q1 | $161M | Buy |
1,353,466
+106,102
| +9% | +$13.6M | 0.01% | 750 |
|
|
2018
Q4 | $136M | Buy |
1,247,364
+12,894
| +1% | +$1.61M | 0.01% | 756 |
|
|
2018
Q3 | $199M | Sell |
1,234,470
-233,003
| -16% | -$31.9M | 0.02% | 717 |
|
|
2018
Q2 | $194M | Sell |
1,467,473
-761,515
| -34% | -$71.8M | 0.02% | 702 |
|
|
2018
Q1 | $165M | Sell |
2,228,988
-145,473
| -6% | -$9.7M | 0.01% | 750 |
|
|
2017
Q4 | $132M | Sell |
2,374,461
-549,081
| -19% | -$29.1M | 0.01% | 868 |
|
|
2017
Q3 | $133M | Sell |
2,923,542
-241,604
| -8% | -$9.66M | 0.01% | 831 |
|
|
2017
Q2 | $107M | Sell |
3,165,146
-31,981
| -1% | -$1.04M | 0.01% | 924 |
|
|
2017
Q1 | $94.6M | Buy |
3,197,127
+559,342
| +21% | +$17.3M | 0.01% | 972 |
|
|
2016
Q4 | $72.4M | Sell |
2,637,785
-322,126
| -11% | -$12.9M | 0.01% | 1076 |
|
|
2016
Q3 | $182M | Sell |
2,959,911
-132,516
| -4% | -$4.01M | 0.02% | 653 |
|
|
2016
Q2 | $59M | Buy |
3,092,427
+625,051
| +25% | +$11.6M | 0.01% | 1103 |
|
|
2016
Q1 | $48.2M | Buy |
2,467,376
+865,658
| +54% | +$15.1M | 0.01% | 1188 |
|
|
2015
Q4 | $61.8M | Buy |
1,601,718
+256,687
| +19% | +$8.32M | 0.01% | 1060 |
|
|
2015
Q3 | $43.2M | Sell |
1,345,031
-234,088
| -15% | -$7.94M | 0.01% | 1257 |
|
|
2015
Q2 | $48M | Sell |
1,579,119
-606,445
| -28% | -$12.4M | 0.01% | 1296 |
|
|
2015
Q1 | $29M | Buy |
2,185,564
+329,575
| +18% | +$4.39M | ﹤0.01% | 1579 |
|
|
2014
Q4 | $26.9M | Buy |
1,855,989
+557,448
| +43% | +$9.44M | ﹤0.01% | 1584 |
|
|
2014
Q3 | $27.4M | Buy |
1,298,541
+223,097
| +21% | +$5.04M | ﹤0.01% | 1512 |
|
|
2014
Q2 | $32M | Sell |
1,075,444
-196,498
| -15% | -$6.21M | ﹤0.01% | 1478 |
|
|
2014
Q1 | $30.6M | Sell |
1,271,942
-74,888
| -6% | -$1.91M | ﹤0.01% | 1483 |
|
|
2013
Q4 | $27.4M | Buy |
1,346,830
+228,285
| +20% | +$6.78M | ﹤0.01% | 1533 |
|
|
2013
Q3 | $52.8M | Buy |
1,118,545
+161,108
| +17% | +$6.2M | 0.01% | 1126 |
|
|
2013
Q2 | $36.4M | Buy |
+957,437
| New | +$34.2M | ﹤0.01% | 1284 |
|
Other funds holding SRPT
EAM
State Street's SRPT Position: Q2 2026 in Review
State Street increased its Sarepta Therapeutics (SRPT) stake by 35% in Q2 2026, buying an estimated $43.6M and bringing the position to 8,916,090 shares worth $160M. The position accounts for ﹤0.01% of the portfolio, ranked #1185.
State Street first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $654M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- State Street held 8,916,090 shares of Sarepta Therapeutics worth $160M as of Q2 2026.
- State Street bought 2,302,776 Sarepta Therapeutics shares in Q2 2026, an estimated $43.6M.
- Sarepta Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1185 holding.
- State Street first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
- State Street's Sarepta Therapeutics position peaked at $654M in Q2 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.